Litao Li

Litao Li


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in ACM Transactions on Privacy and Security
Verified
Journal Article
Open access
LLLitao Li
Litao Li
SDSteven H. H. Ding
Steven H. H. Ding
YTYuan Tian
Yuan Tian
Benjamin C. M. FungBenjamin C. M. Fung
Benjamin C. M. Fung
PCPhilippe Charland
Philippe Charland
CCCongwei Chen
Congwei Chen
Software vulnerabilities have been posing tremendous reliability threats to the general public as well as critical infrastructures, and there have been many studies aiming to detect and mitigate software defects at the binary level. Most of the standard practices leverage both static and dynamic analysis, which have several drawbacks like heavy manual workload and high complexity. Existing deep learning-based solutions not only suffer to capture the complex relationships among different variables from raw binary code but also lack the explainability required for humans to verify, evaluate, and patch the detected bugs.We propose VulANalyzeR, a deep learning-based model, for automated binary vulnerability detection, Common Weakness Enumeration-type classification, and root cause analysis to enhance safety and security. VulANalyzeR features sequential and topological learning through recurrent units and graph convolution to simulate how a program is executed. The attention mechanism is integrated throughout the model, which shows how different instructions and the corresponding states contribute to the final classification. It also classifies the specific vulnerability type through multi-task learning as this not only provides further explanation but also allows faster patching for zero-day vulnerabilities. We show that VulANalyzeR achieves better performance for vulnerability detection over the state-of-the-art baselines. Additionally, a Common Vulnerability Exposure dataset is used to evaluate real complex vulnerabilities. We conduct case studies to show that VulANalyzeR is able to accurately identify the instructions and basic blocks that cause the vulnerability even without given any prior knowledge related to the locations during the training phase.

22 October 2024 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
YLYing Lou
Ying Lou
ZLZhongshuo Liu
Zhongshuo Liu
YJYingxiao Ji
Yingxiao Ji
JCJinming Cheng
Jinming Cheng
CZCongying Zhao
Congying Zhao
LLLitao Li
Litao Li
Background: Early rehabilitation after acute ischemic stroke (AIS) contributes to functional recovery. However, the optimal time for starting rehabilitation remains a topic of ongoing investigation. This article aims to shed light on the safety and efficacy of very early rehabilitation (VER) initiated within 48 h of stroke onset.Methods: A systematic search in PubMed, Embase, Cochrane Library, and Web of Science databases was conducted from inception to January 20, 2024. Relevant literature on VER in patients with AIS was reviewed and the data related to favorable and adverse clinical outcomes were collected for meta-analysis. Subgroup analysis was conducted at different time points, namely at discharge and at three and 12 months. Statistical analyses were performed with the help of the Meta Package in STATA Version 15.0.Results: A total of 14 randomized controlled trial (RCT) studies and 3,039 participants were included in the analysis. VER demonstrated a significant association with mortality [risk ratio (RR) = 1.27, 95% confidence interval (CI) (1.00, 1.61)], ability of daily living [weighted mean difference (WMD) = 6.90, 95% CI (0.22, 13.57)], and limb motor function [WMD = 5.02, 95% CI (1.63, 8.40)]. However, no significant difference was observed between the VER group and the control group in adverse events [RR = 0.89, 95% CI (0.79, 1.01)], severity of stroke [WMD = 0.52, 95% CI (−0.04, 1.08)], degree of disability [RR = 1.06, 95% CI (0.93, 1.20)], or recovery of walking [RR = 0.98, 95% CI (0.94, 1.03)] after stroke. Subgroup analysis revealed that VER reduced the risk of adverse events in the late stage (at three and 12 months) [RR = 0.86, 95% CI (0.74, 0.99)] and degree of disability at 12 months [RR = 1.28, 95% CI (1.03, 1.60)], and improved daily living ability at 3 months [WMD = 4.26, 95% CI (0.17, 8.35)], while increasing severity of stroke during hospitalization [WMD = 0.81, 95% CI (0.01, 1.61)].Conclusion: VER improves activities of daily living (ADLs) and lowers the incidence of long-term complications in stroke survivors. However, premature or overly intense rehabilitation may increase mortality in patients with AIS during the acute phase. PROSPERO registration number: CRD42024508180.Systematic review registration: This systematic review was registered with PROSPERO (https://www.crd.york.ac.uk/PROSPERO/). PROSPERO registration number: CRD42024508180.

12 July 2012 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
YLYing-Mei Lu
Ying-Mei Lu
RTRong-Rong Tao
Rong-Rong Tao
JHJi-Yun Huang
Ji-Yun Huang
LLLitao Li
Litao Li
MLMei-Hua Liao
Mei-Hua Liao
FHFeng Han
Feng Han
Background: The cerebral microvascular occlusion elicits microvascular injury which mimics the different degrees of stroke severity observed in patients, but the mechanisms underlying these embolic injuries are far from understood. The Fas ligand (FasL)-Fas system has been implicated in a number of pathogenic states. Here, we examined the contribution of microglia-derived FasL to brain inflammatory injury, with a focus on the potential to suppress the FasL increase by inhibition of the P2X7-FasL signaling with pharmacological or genetic approaches during ischemia. Methods: The cerebral microvascular occlusion was induced by microsphere injection in experimental animals. Morphological changes in microglial cells were studied immunohistochemically. The biochemical analyses were used to examine the intracellular changes of P2X7/FasL signaling. The BV-2 cells and primary microglia from mice genetically deficient in P2X7 were used to further establish a linkage between microglia activation and FasL overproduction. Results: The FasL expression was continuously elevated and was spatiotemporally related to microglia activation following microsphere embolism. Notably, P2X7 expression concomitantly increased in microglia and presented a distribution pattern that was similar to that of FasL in ED1-positive cells at pathological process of microsphere embolism. Interestingly, FasL generation in cultured microglia cells subjected to oxygen-glucose deprivation-treated neuron-conditioned medium was prevented by the silencing of P2X7. Furthermore, FasL induced the migration of BV-2 microglia, whereas the neutralization of FasL with a blocking antibody was highly effective in inhibiting ischemia-induced microglial mobility. Similar results were observed in primary microglia from wild-type mice or mice genetically deficient in P2X7. Finally, the degrees of FasL overproduction and neuronal death were consistently reduced in P2X7 −/− mice compared with wild-type littermates following microsphere embolism insult. Conclusion: FasL functions as a key component of an immunoreactive response loop by recruiting microglia to the lesion sites through a P2X7-dependent mechanism. The specific modulation of P2X7/FasL signaling and aberrant microglial activation could provide therapeutic benefits in acute and subacute phase of cerebral microembolic injury.

16 June 2023 in Medicine
Verified
Journal Article
Open access
MJMan Jin
Man Jin
LYLv pei Yuan
Lv pei Yuan
HLHao Liang
Hao Liang
ZTZhenjie Teng
Zhenjie Teng
CGChenyang Gao
Chenyang Gao
LLLitao Li
Litao Li
The triglyceride-glucose (TyG) index has been proposed as a new marker for insulin resistance, which is associated with a risk of major depressive disorder (MDD). This study aims to explore whether the TyG index is correlated with MDD. In total, 321 patients with MDD and 325 non-MDD patients were included in the study. The presence of MDD was identified by trained clinical psychiatrists using the International Classification of Diseases 10th Revision. The TyG index was calculated as follows: Ln (fasting triglyceride [mg/dL] × fasting glucose [mg/dL]/2). The results revealed that the MDD group presented higher TyG index values than the non-MDD group (8.77 [8.34–9.17] vs 8.62 [8.18–9.01], P < .001). We also found significantly higher morbidity of MDD in the highest TyG index group than in the lower TyG index group (59.9% vs 41.4%, P < .001). Binary logistic regression revealed that TyG was an independent risk factor for MDD (odds ratio [OR] 1.750, 95% confidence interval: 1.284–2.384, P < .001). We further assessed the effect of TyG on depression in sex subgroups. The OR was 3.872 (OR 2.014, 95% confidence interval: 1.282–3.164, P = .002) for the subgroup of men. It is suggested that the TyG index could be closely associated with morbidity in MDD patients; thus, it may be a valuable marker for identifying MDD.

1 June 2020 in Antioxidants
Verified
Journal Article
Open access
PDF file
LLLitao Li
Litao Li
ATArtak Tovmasyan
Artak Tovmasyan
Huaxin ShengHuaxin Sheng
Huaxin Sheng
BXBin Xu
Bin Xu
RSRomulo S. Sampaio
Romulo S. Sampaio
ISIvan Spasojevic
Ivan Spasojevic
Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, (H2O)MnTnHex-2-PyP5+ (MnHex) carrying long hexyl chains, is a lipophilic mimic of superoxide dismutase (SOD) and a redox-active drug candidate. MnHex crosses the blood–brain barrier, and improved neurologic outcome and decreased infarct size and inflammation in a rat middle cerebral artery occlusion (MCAO) ischemic stroke model. Yet, the dose and the therapeutic efficacy of Mn porphyrin were limited by an adverse effect of arterial hypotension. An equally lipophilic Fe analog, (OH)FeTnHex-2-PyP4+ (FeHex), is as redox-active and potent SOD mimic in vitro. With different coordination geometry of the metal site, FeHex has one hydroxo (OH) ligand (instead of water) bound to the Fe center in the axial position. It has ~2 orders of magnitude higher efficacy than MnHex in an SOD-deficient E. coli model of oxidative stress. In vivo, it does not cause arterial hypotension and is less toxic to mice. We thus evaluated FeHex versus MnHex in a rodent MCAO model. We first performed short- and long-term pharmacokinetics (PK) of both porphyrins in the plasma, brain, and liver of rats and mice. Given that damage to the brain during stroke occurs very rapidly, fast delivery of a sufficient dose of drug is important. Therefore, we aimed to demonstrate if, and how fast after reperfusion, Fe porphyrin reaches the brain relative to the Mn analog. A markedly different plasma half-life was found with FeHex (~23 h) than with MnHex (~1.4 h), which resulted in a more than 2-fold higher plasma exposure (AUC) in a 7-day twice-daily treatment of rats. The increased plasma half-life is explained by the much lower liver retention of FeHex than typically found in Mn analogs. In the brain, a 3-day mouse PK study showed similar levels of MnHex and FeHex. The same result was obtained in a 7-day rat PK study, despite the higher plasma exposure of FeHex. Importantly, in a short-term PK study with treatment starting 2 h post MCAO, both Fe- and Mn- analogs distributed at a higher level to the injured brain hemisphere, with a more pronounced effect observed with FeHex. While a 3-day mouse MCAO study suggested the efficacy of Fe porphyrin, in a 7-day rat MCAO study, Mn-, but not Fe porphyrin, was efficacious. The observed lack of FeHex efficacy was discussed in terms of significant differences in the chemistry of Fe vs. the Mn center of metalloporphyrin; relative to MnHex, FeHex has the propensity for axial coordination, which in vivo would preclude the reactivity of the Fe center towards small reactive species.

1 January 2020 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
OGon behalf of Stroke Imaging Package Study of Intracranial Atherosclerosis (SIPS-ICAS) study group
on behalf of Stroke Imaging Package Study of Intracranial Atherosclerosis (SIPS-ICAS) study group
QLQianqian Lin
Qianqian Lin
XLXiaoyun Liu
Xiaoyun Liu
BCBeilei Chen
Beilei Chen
DTDAI-SHI TIAN
DAI-SHI TIAN
WXWei-Hai Xu
Wei-Hai Xu
Background: Intracranial atherosclerosis (ICAS) is a major cause of stroke worldwide. However, much remains unknown regarding its underlying pathophysiology. High-resolution magnetic resonance imaging (HR-MRI) can clearly display intracranial vessel wall lesions in vivo. The aim of stroke imaging package study of ICAS (SIPS-ICAS) study is to explore the stroke mechanisms of symptomatic ICAS, the dynamic changes under aggressive medical treatment and their associations with clinical events using conventional MRI sequences plus HR-MRI. Methods: This is a multicenter, prospective, cohort study recruiting first-ever acute ischemic stroke patients attributed to intracranial large artery stenosis (>50% or occlusion). Subjects undergo a pre-designed stroke imaging packages at baseline and are recommended to receive aggressive medical treatments. Participants will be followed up for functional outcome, stroke recurrence, and death events at 3, 6 and 12 months and retake HR-MRI imaging at 6 months. Results: Enrollment began in November 2018 and 96 patients have been enrolled as of September 2019. Conclusions: The SIPS-ICAS study will provide insights into the pathophysiology of ICAS and identify specific imaging markers for risk stratification and prognosis prediction. At the same time, the feasibility and validity of the new stroke imaging package including HR-MRI will be assessed, which is promising for clinical routine use.